These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33978322)

  • 1. Identifying miRNAs in multiple sclerosis gray matter lesions that correlate with atrophy measures.
    Tripathi A; Pandit I; Perles A; Zhou Y; Cheng F; Dutta R
    Ann Clin Transl Neurol; 2021 Jun; 8(6):1279-1291. PubMed ID: 33978322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.
    Regev K; Healy BC; Khalid F; Paul A; Chu R; Tauhid S; Tummala S; Diaz-Cruz C; Raheja R; Mazzola MA; von Glehn F; Kivisakk P; Dupuy SL; Kim G; Chitnis T; Weiner HL; Gandhi R; Bakshi R
    JAMA Neurol; 2017 Mar; 74(3):275-285. PubMed ID: 28114622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of disease-related miRNAs in white-matter lesions of progressive multiple sclerosis brains.
    Tripathi A; Volsko C; Datta U; Regev K; Dutta R
    Ann Clin Transl Neurol; 2019 May; 6(5):854-862. PubMed ID: 31139683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Proteomic Profiling Identifies Reciprocal Expression of Mitochondrial Proteins Between White and Gray Matter Lesions From Multiple Sclerosis Brains.
    Rai NK; Singh V; Li L; Willard B; Tripathi A; Dutta R
    Front Neurol; 2021; 12():779003. PubMed ID: 35002930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
    Arnold DL; Piani-Meier D; Bar-Or A; Benedict RH; Cree BA; Giovannoni G; Gold R; Vermersch P; Arnould S; Dahlke F; Hach T; Ritter S; Karlsson G; Kappos L; Fox RJ;
    Mult Scler; 2022 Sep; 28(10):1526-1540. PubMed ID: 35261318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA profiles of MS gray matter lesions identify modulators of the synaptic protein synaptotagmin-7.
    Fritsche L; Teuber-Hanselmann S; Soub D; Harnisch K; Mairinger F; Junker A
    Brain Pathol; 2020 May; 30(3):524-540. PubMed ID: 31663645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroinflammatory component of gray matter pathology in multiple sclerosis.
    Herranz E; Giannì C; Louapre C; Treaba CA; Govindarajan ST; Ouellette R; Loggia ML; Sloane JA; Madigan N; Izquierdo-Garcia D; Ward N; Mangeat G; Granberg T; Klawiter EC; Catana C; Hooker JM; Taylor N; Ionete C; Kinkel RP; Mainero C
    Ann Neurol; 2016 Nov; 80(5):776-790. PubMed ID: 27686563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological differences between white and grey matter multiple sclerosis lesions.
    Prins M; Schul E; Geurts J; van der Valk P; Drukarch B; van Dam AM
    Ann N Y Acad Sci; 2015 Sep; 1351():99-113. PubMed ID: 26200258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gray Matter Atrophy in the Cortico-Striatal-Thalamic Network and Sensorimotor Network in Relapsing-Remitting and Primary Progressive Multiple Sclerosis.
    Cao Y; Diao W; Tian F; Zhang F; He L; Long X; Zhou F; Jia Z
    Neuropsychol Rev; 2021 Dec; 31(4):703-720. PubMed ID: 33582965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the miRNA-mRNA regulatory network in multiple sclerosis.
    Yang Q; Pan W; Qian L
    Neurol Res; 2017 Feb; 39(2):142-151. PubMed ID: 27809691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
    Kim G; Chu R; Yousuf F; Tauhid S; Stazzone L; Houtchens MK; Stankiewicz JM; Severson C; Kimbrough D; Quintana FJ; Chitnis T; Weiner HL; Healy BC; Bakshi R
    Int J Neurosci; 2017 Nov; 127(11):971-980. PubMed ID: 28100092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single scan quantitative gradient recalled echo MRI for evaluation of tissue damage in lesions and normal appearing gray and white matter in multiple sclerosis.
    Xiang B; Wen J; Cross AH; Yablonskiy DA
    J Magn Reson Imaging; 2019 Feb; 49(2):487-498. PubMed ID: 30155934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment.
    van Wageningen TA; Vlaar E; Kooij G; Jongenelen CAM; Geurts JJG; van Dam AM
    Acta Neuropathol Commun; 2019 Dec; 7(1):206. PubMed ID: 31829283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of global and regional gray matter volume decrease in multiple sclerosis.
    Grothe M; Lotze M; Langner S; Dressel A
    J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs in gray and white matter multiple sclerosis lesions: impact on pathophysiology.
    Teuber-Hanselmann S; Meinl E; Junker A
    J Pathol; 2020 Apr; 250(5):496-509. PubMed ID: 32073139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional patterns of grey matter atrophy and magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups: a voxel-based analysis study.
    Mallik S; Muhlert N; Samson RS; Sethi V; Wheeler-Kingshott CA; Miller DH; Chard DT
    Mult Scler; 2015 Apr; 21(4):423-32. PubMed ID: 25145689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis.
    Steenwijk MD; Daams M; Pouwels PJ; J Balk L; Tewarie PK; Geurts JJ; Barkhof F; Vrenken H
    Hum Brain Mapp; 2015 May; 36(5):1796-807. PubMed ID: 25627545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.
    Pontillo G; Cocozza S; Lanzillo R; Russo C; Stasi MD; Paolella C; Vola EA; Criscuolo C; Borrelli P; Palma G; Tedeschi E; Morra VB; Elefante A; Brunetti A
    AJNR Am J Neuroradiol; 2019 Jan; 40(1):99-106. PubMed ID: 30573464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis.
    Jonkman LE; Rosenthal DM; Sormani MP; Miles L; Herbert J; Grossman RI; Inglese M
    PLoS One; 2015; 10(10):e0129380. PubMed ID: 26485710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.